Clinical trials
Primary Biliary Cholangitis clinical trials
Below are recruiting primary biliary cholangitis clinical trials, each written for real people, not researchers. We’re tracking 44 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07387549RecruitingPhase 3
Elafibranor for primary sclerosing cholangitis
This study tests a new medication called elafibranor for adults with primary sclerosing cholangitis (PSC), a chronic liver disease. It aims to see if elafibranor can safely help improve liver health when compared to no treatment.
Chandler, ArizonaAges 18–75 - NCT06286709RecruitingPhase 2
Fecal transplant for PSC and colitis
This trial tests whether a fecal (stool) transplant from a healthy donor can help people with both PSC and inflammatory bowel disease. It aims to see if the treatment can improve liver health and reduce inflammation. You must have early to moderate liver scarring and be on stable medications.
BirminghamAges 18 years+ - NCT07598669Recruiting
Austrian Primary Biliary Cholangitis Registry Study
This is a registry study that collects health information from people with primary biliary cholangitis (PBC), a rare liver disease where the immune system damages bile ducts. By joining, you help researchers better understand PBC and improve care for patients with this condition.
Klagenfurt, CarinthiaAges 18 years+ - NCT07424677RecruitingPhase 3
Saroglitazar for PBC with incomplete UDCA response
This trial tests a new oral medication, saroglitazar magnesium, for people with Primary Biliary Cholangitis (PBC) who have not improved enough on standard therapy (UDCA) or cannot tolerate it. The goal is to see if it can help control liver enzymes and improve outcomes.
Lakewood Rch, FloridaAges 18–80 - NCT07296458RecruitingPhase 3
Fenofibrate for first-line treatment of primary biliary cholangitis
This study tests whether fenofibrate, a medicine that lowers fats in the blood, can help people with primary biliary cholangitis (a chronic liver disease) who haven't had treatment before. It aims to see if it is safe and effective as a first treatment option.
Xi'an, ShaanxiAges 18–75 - NCT07282353RecruitingPhase 3
Study of CS0159 for primary biliary cholangitis with poor UDCA response
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
Hefei, AnhuiAges 18–75 - NCT04650243RecruitingPhase 4
Testing whether lowering UDCA helps people with PBC
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
BeijingAges 18 years+ - NCT07149675Recruiting
Long-term study for primary biliary cholangitis patients
This study tracks patients with primary biliary cholangitis (PBC) over time to understand long-term outcomes. It aims to gather information that could improve care and management for people with PBC.
Beijing, Select A State Or ProvinceAges Any age - NCT06443606RecruitingPhase 3
Bezafibrate for primary biliary cholangitis with incomplete UDCA response
This trial tests if adding bezafibrate (200 mg or 400 mg) to standard UDCA treatment can improve liver function in people with primary biliary cholangitis whose UDCA alone isn't working well enough.
ParisAges 18–80 - NCT05876182RecruitingPhase 2
Vancomycin for primary sclerosing cholangitis
This Phase 2 study tests whether the antibiotic vancomycin can improve primary sclerosing cholangitis (PSC), a long-term bile-duct disease. You may be eligible if you have confirmed PSC and certain blood test and safety criteria, and you can follow medication washout rules.
Monza, Monza E BrianzaAges 15–70 - NCT06519162Recruiting
Liver-gut link study for liver disease patients and their families
This study looks at how gut bacteria differ in people with specific liver diseases and their household contacts. It may help researchers understand the connection between the liver and gut.
Daejeon, Jung-guAges 19 years+ - NCT05912387RecruitingEarly Phase 1
Testing statin treatment in primary sclerosing cholangitis
This early study looks at how a statin (cholesterol-lowering medicine) affects people with primary sclerosing cholangitis (PSC) by measuring changes using multiple types of health data. It may help researchers understand which people benefit and how PSC biology changes with treatment.
Stanford, CaliforniaAges 18–80 - NCT02931513Recruiting
Blood marker test in newly diagnosed PBC patients
This study looks at how a specific blood marker (sCD163) changes in people newly diagnosed with primary biliary cholangitis (PBC). It’s mainly meant to see whether this marker could help predict treatment response, especially before starting UDCA.
Aarhus C, Central JutlandAges 18 years+ - NCT04753996Recruiting
Testing bile-based “mini-liver” samples in PSC and non-PSC groups
This study collects bile and uses it to grow small lab models (organoids) from people with primary sclerosing cholangitis (PSC) and from people without PSC. Researchers want to better understand how PSC changes bile cells, which could improve future diagnosis or treatments.
Rochester, MinnesotaAges 18–85 - NCT06699121RecruitingPhase 2
Testing LB-P8 for people with primary sclerosing cholangitis
This trial tests a new treatment called LB-P8 for people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if LB-P8 is safe and can help slow the disease down. You may join if you meet certain health requirements.
Sacramento, CaliforniaAges 18–75 - NCT06197308RecruitingEarly Phase 1
Testing a mouth bacteria treatment for PSC
This study tests whether a treatment made from mouth bacteria can help people with primary sclerosing cholangitis (PSC). It aims to see if it's safe and improves health.
Minneapolis, MinnesotaAges 18–76 - NCT05835505RecruitingPhase 2
Detox medicine study for primary sclerosing cholangitis
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
Chestnut Hill, MassachusettsAges 18–75 - NCT03175471Recruiting
MRI study of blood-vessel and tissue signs in child liver disease
This trial uses MRI scans to look for “biomarkers,” which are measurable signs in the liver, to better understand autoimmune liver diseases in children and teens. It may help doctors track disease and improve care by finding imaging patterns linked to illness.
Cincinnati, OhioAges 6–23 - NCT03178630Recruiting
MRI scans to track outcomes in children with autoimmune liver disease
This study uses MRI scans to find “biomarkers,” or imaging clues, that may help predict how autoimmune liver conditions will progress in children and young adults. If you qualify, you may get MRI imaging to see whether it relates to future health outcomes.
Cincinnati, OhioAges 6–23 - NCT06671418Enrolling by invitationPhase 3
Stenting vs drainage for blocked bile ducts from cancer
This study compares two ways to open blocked bile ducts near the liver due to cancer that cannot be removed. One method uses a stent placed through the skin (percutaneous stenting), and the other uses a tube placed through a scope (endoscopic drainage). The goal is to see which approach works better for relieving jaundice and improving quality of life.
RotterdamAges Any age
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary biliary cholangitis?
- Yes. Clin2 currently lists 44 recruiting primary biliary cholangitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary biliary cholangitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary biliary cholangitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.